share_log

JMP Securities Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $35

JMP Securities Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $35

JMP证券保持英特格拉生命科学市场优势,将价格目标下调至35美元
Benzinga ·  07/30 11:23  · 评级/大行评级

JMP Securities analyst David Turkaly maintains Integra Lifesciences (NASDAQ:IART) with a Market Outperform and lowers the price target from $40 to $35.

JMP证券的分析师David Turkaly维持Integra Lifesciences (NASDAQ:IART)的市场表现,并将价格目标从40美元降至35美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发